Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib plus docetaxel versus docetaxel in previously treated advanced non-squamous non-small-cell lung cancer
ChiCTR1800017114Phase 4Not yet recruiting
- Sponsor
- The 2nd Affiliated Hospital of Chongqing Medical University
- Start
- Jul 2018
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of anlotinib and docetaxel in non-small cell lung cancer (NSCLC) (2 arms), sponsored by The 2nd Affiliated Hospital of Chongqing Medical University. Primary endpoint: Progression-free survival. Planned start Jul 2018; status: not yet recruiting.
02
Drugs
anlotinibdocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR1800017114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800017114.